1-3 of 3
Charles S. Fuchs
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer

Justin H. Lo, Liangliang Hao, Mandar D. Muzumdar, Srivatsan Raghavan, Ester J. Kwon, Emilia M. Pulver, Felicia Hsu, Andrew J. Aguirre, Brian M. Wolpin, Charles S. Fuchs, William C. Hahn, Tyler Jacks, Sangeeta N. Bhatia
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (11): 2377–2388.
https://doi.org/10.1158/1535-7163.MCT-17-1090
Published: 02 November 2018
View article titled, iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer
Open the PDF for iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer in another window
Includes: Multimedia, Supplementary data
Journal Articles

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer

Josep Tabernero, Atsushi Ohtsu, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Jaffer A. Ajani, Jiri Tomasek, Howard Safran, Kumari Chandrawansa, Yanzhi Hsu, Michael Heathman, Azhar Khan, Lan Ni, Allen S. Melemed, Ling Gao, David Ferry, Charles S. Fuchs
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (10): 2215–2222.
https://doi.org/10.1158/1535-7163.MCT-16-0895
Published: 02 October 2017
View article titled, Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer
Open the PDF for Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer in another window
Includes: Supplementary data
Journal Articles

Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I

Robert B. Lobell, Dongming Liu, Carolyn A. Buser, Joseph P. Davide, Elizabeth DePuy, Kelly Hamilton, Kenneth S. Koblan, Yih Lee, Scott Mosser, Sherri L. Motzel, James L. Abbruzzese, Charles S. Fuchs, Eric K. Rowinsky, Eric H. Rubin, Sunil Sharma, Paul J. Deutsch, Kathryn E. Mazina, Briggs W. Morrison, Lynne Wildonger, Siu-Long Yao, Nancy E. Kohl
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2002) 1 (9): 747–758.
Published: 01 July 2002
View article titled, Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I
Open the PDF for Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I in another window